Which Pharmas Still Have Cash?

Pharmaceutical mergers-and-acquisitions activity has been jumping for the past few months, but the consolidation can't go on forever. With Roche, Merck (NYSE: MRK  ) , and Pfizer (NYSE: PFE  ) out of the running, who's left?

GlaxoSmithKline (NYSE: GSK  ) looks like it's making a move to stock up on cash so that it can buy or license while the pickings are cheap. Last year, the company said that it would forgo any stock buybacks, and last week it sold off $256 million of stock in Quest Diagnostics to add to its nest egg.

The British drugmaker isn't the only one with cash burning a hole in its pocket, just look at how much cash these other pharmaceutical companies have on their books.

Company

Cash and short-term investments (billions)

GlaxoSmithKline

$8.5*

Bristol-Myers Squibb (NYSE: BMY  )

$8.3

Johnson & Johnson (NYSE: JNJ  )

$12.8

Eli Lilly (NYSE: LLY  )

$5.9

Novartis (NYSE: NVS  )

$5.8

Source: Capital IQ, a division of Standard & Poor's.
*Includes the $256 million added last week.

Sure, none of these match the $26 billion that Pfizer had before it announced the acquisition of Wyeth, but they don't really need such a large sum since most of them are unlikely to do a large deal. For instance, Glaxo has been using call options to acquire the rights to drugs, and Johnson & Johnson has made it a tradition to pick up small companies to bolt onto the family tree.

And there's lots of cheap pickings. According to Rodman & Renshaw, there are 81 biotechs trading at less than cash on hand. That's a lot of companies that could be bought for next to nothing or that might be willing to part with their drug candidates just to stay alive for a few more months. Myriad Genetics, for instance, recently bought the complete rights to Panacos Pharmaceuticals' HIV drug candidate, bevirimat, for a measly $7 million.

There's still plenty of cash to be deployed, just don't expect it to be put out in large acquisitions.

Deploy to further Foolishness:

GlaxoSmithKline and Johnson & Johnson are Motley Fool Income Investor selections. Quest Diagnostics and Pfizer are Inside Value recommendations. Novartis is a Global Gains recommendation. Try any of our Foolish newsletters today, free for 30 days

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool's disclosure policy is almost done painting the digital folder where it lives.


Read/Post Comments (0) | Recommend This Article (8)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 858222, ~/Articles/ArticleHandler.aspx, 10/21/2014 4:13:15 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement